Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.

Autor: Khalizieva A; Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands.; Division of Cell Systems and Drug Safety, Leiden Academic Center for Drug Research, Leiden University, 2333 AL Leiden, The Netherlands., Moser SC; Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; Oncode Institute, 3521 AL Utrecht, The Netherlands., Bouwman P; Division of Cell Systems and Drug Safety, Leiden Academic Center for Drug Research, Leiden University, 2333 AL Leiden, The Netherlands., Jonkers J; Division of Molecular Pathology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; j.jonkers@nki.nl s.moser@nki.nl r.j.p.bouwman@lacdr.leidenuniv.nl.; Oncode Institute, 3521 AL Utrecht, The Netherlands.

Publikováno v: Genes & development [Genes Dev] 2024 Nov 07. Date of Electronic Publication: 2024 Nov 07.

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.

Autor: Ter Brugge P; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., Moser SC; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., Bièche I; Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Kristel P; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., Ibadioune S; Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Eeckhoutte A; INSERM U830, Institut Curie, PSL University, 75005, Paris, France.; Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., de Bruijn R; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., van der Burg E; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., Lutz C; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., Annunziato S; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., de Ruiter J; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., Masliah Planchon J; Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Vacher S; Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Courtois L; Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., El-Botty R; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Dahmani A; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Montaudon E; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Morisset L; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Sourd L; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Huguet L; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Derrien H; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Nemati F; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Chateau-Joubert S; BioPôle Alfort, Ecole Nationale Vétérinaire d'Alfort, 94704, Maisons Alfort, France., Larcher T; INRA, APEX-PAnTher, Oniris, 44300, Nantes, France., Salomon A; Department of Pathology, Institut Curie, PSL University, 75005, Paris, France., Decaudin D; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Reyal F; Department of Surgery, Institut Curie, PSL University, 75005, Paris, France., Coussy F; Department of Medical Oncology, Institut Curie, PSL University, 75005, Paris, France., Popova T; INSERM U830, Institut Curie, PSL University, 75005, Paris, France.; Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Wesseling J; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands., Stern MH; Genetics Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France.; INSERM U830, Institut Curie, PSL University, 75005, Paris, France.; Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France., Jonkers J; Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands. j.jonkers@nki.nl., Marangoni E; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, 26 Rue d'Ulm, 75005, Paris, France. Elisabetta.marangoni@curie.fr.

Publikováno v: Nature communications [Nat Commun] 2023 Apr 07; Vol. 14 (1), pp. 1958. Date of Electronic Publication: 2023 Apr 07.